Aims: Nasal glucagon (NG) is a nasally-administered glucagon powder, absorbed through the nasal mucosa, designed for treatment of severe hypoglycaemia. This study evaluated the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of NG in otherwise healthy participants with common colds and after recovery from cold symptoms, with and without concomitant nasal decongestant. Results: NG was well tolerated, without serious adverse events. Common adverse events (transient lacrimation, nasal discomfort, rhinorrhea and nausea) were more frequent in both Cohorts 1 and 2 during nasal congestion. Glucagon levels peaked 18 minutes post-dose and glucose levels peaked 30 to 42 minutes post-dose in all groups. Nasal congestion, with or without concomitant nasal decongestant, did not significantly affect PK of NG. Although glucose AUECs 0-t was different between Cohort 1 with nasal congestion and Cohort 2, glucose concentrations at 30 minutes appeared similar in all groups.
hypoglycaemia may influence patients towards higher blood glucose, increasing risks of hyperglycaemia-associated complications. 3, 4 Glucagon is an effective treatment for severe hypoglycaemia.
Aqueous glucagon is unstable; thus, glucagon emergency kits contain powdered glucagon which must be reconstituted before being administered. 5, 6 When treating individuals who are disoriented, unconscious, seizing or convulsing in an emergency situation, people without medical training may find the reconstitution process difficult, time-consuming and prone to error. Delays, errors, or failure to administer glucagon during severe hypoglycaemia may negatively impact patient outcomes. 7 Recently, a study has shown that reconstituted recombinant glucagon delivered intranasally in euglycaemic individuals is rapidly absorbed into the systemic circulation and acts to increase blood glucose. 8 A form of glucagon that does not require reconstitution could be more beneficial, as it could be administered more quickly.
Nasal glucagon (NG), a novel drug/device combination product, is being developed for treatment of severe hypoglycaemia. The needlefree, ready-to-use device delivers a dry powdered formulation into the patient's nostril. Administration of injectable glucagon requires several steps, including reconstitution, and is prone to error. In a simulation study, NG administration was faster and provided greater probability of success in delivering the full dose by caregivers (94% vs 13%) and others (93% vs 0%), with fewer errors compared to injectable glucagon. 9 Nasal administration is effective for delivery of medications and vaccines. 10 The human nasal cavity has a volume of 15 to 20 mL and a surface area of approximately 150 cm 2 . Because of this large surface area and the rich blood supply, medications can be readily absorbed through the nasal mucosa. 10 Most commonly, nasallyadministered drugs are for the treatment of acute or chronic nasal symptoms (eg, decongestants). However, drugs that act systemically are also administered nasally, 10 including treatments for migraine (eg, zolmitriptan and sumatriptan), 10 pain (eg, fentanyl) 10, 11 and drug overdose (eg, naloxone). 12 Lipophilic drugs are well absorbed from the nasal cavity and often have pharmacokinetic profiles and bioavailability comparable to intravenously-injected drugs. 13 The NG formulation contains the lipophilic excipient dodecylphosphocholine, which helps to enhance absorption. Dodecylphosphocholine contains a choline group, a phosphate group and a saturated aliphatic chain. All 3 moieties are present in phospholipids and lecithins which are ubiquitous in mammalian cell membranes. The synthetic glucagon in the formulation is a single-chain, 29-amino acid polypeptide identical to the human recombinant DNA-derived glucagon used in injectable emergency kits.
NG is delivered with a single-use device, inserted into the patient's nostril. When the plunger on the device is depressed, glucagon powder is propelled into the anterior region of the nasal cavity ( Figure 1) . 14 The powder then dissolves and is passively absorbed into the blood stream via the moist membrane of the nasal mucosa without requiring the patient to actively inhale or breathe deeply.
NG was well-tolerated in preclinical studies 15 and in clinical trials in adult and paediatric patients with T1D. [16] [17] [18] In a crossover study of 75 adults with T1D, a 3-mg NG dose was noninferior to 1 mg injectable glucagon in treating insulin-induced hypoglycaemia. 17 NG was also effective in treating naturally-occurring hypoglycaemia in home and school settings in children and adolescents, as well as in home and work settings in adults with T1D. 18, 19 To date, all studies of NG have been conducted in individuals without notable pre-existing nasal congestion. However, common cold and associated nasal congestion occur frequently. In one survey, 85% of respondents reported experiencing at least 1 cold within the past year;
nasal congestion was among the most common cold symptoms reported. 20 Moreover, some congestion in the nasal passageways is common even in healthy individuals. 21 Therefore, it is important to understand whether the pharmacokinetics (PK) and pharmacodynamics (PD) of NG are affected when nasal congestion is present. Nasal decongestants used for the treatment of cold symptoms may also alter blood glucose levels, 22 as well as affect absorption of nasally-administered medications. 11 This study, therefore, enrolled participants with common cold, and compared the effects of NG in participants with nasal congestion and after recovery from cold symptoms, as well as in participants with nasal congestion treated with a decongestant. 2.1 | Eligible participants were enrolled into two cohorts.
| MATERIAL AND METHODS

| Cohort 1
The first 18 participants enrolled were assigned to Cohort 1. These participants received NG treatment twice: first, while suffering from untreated cold symptoms, and again 7 to 28 days later (≥2 days after recovery from cold symptoms). Participants were required to have a Jackson cold scale score of 0 before the second NG treatment.
| Cohort 2
The subsequent 18 participants enrolled, also experiencing common cold with nasal congestion, were assigned to Cohort 2. These participants received NG only once. Two hours before NG administration, they were treated with nasal decongestant (oxymetazoline), sprayed twice into each nostril.
| NG administration and study procedures
All participants fasted for 10 hours (overnight) before a single 3-mg 
| Analytical methods
Glucagon levels in plasma samples were analysed using a radioimmunoassay (20 pg/mL quantification limit; Millipore Human Glucagon Assay, performed by Northwest Lipid Metabolism and Diabetes
Research Laboratories, University of Washington, Seattle, Washington). Plasma glucose was measured using a Synchron ® System, which determines GLUCm concentration by an oxygen rate method using a Beckman Coulter Oxygen electrode (GammaDynacare Medical Laboratories, St-Laurent, Québec, Canada). Total nasal and non-nasal symptom scores at pre-glucagon and various post-glucagon administration time-points were summarized by analysis group with descriptive statistics including mean and standard error.
| Safety and tolerability
As a post-hoc analysis, percentages of participants with a total nasal and non-nasal symptom score ≥2 at pre-glucagon and various post-glucagon administration time-points were also summarized by analysis group.
Change in vital signs from 1 h pre-to 45 minutes post-glucagon administration was summarized by analysis group. Within-group difference was assessed using Wilcoxon Signed Rank test. SAS version 9.1 or higher (SAS Institute Inc., Cary, North Carolina) was used.
Unless otherwise specified, all tests of statistical significance were evaluated at a nominal level of 0.05 using 2-tailed test procedures.
| Power calculations
To achieve statistical power of ≥80% to demonstrate that nasal decongestant use had no significant impact on the glucose AUEC 0-t (assuming true mean difference is zero) and allowing one standard deviation (1.35 hour*mmol/L) as acceptable difference for equivalence, 18 participants per cohort were required; this also provided ≥90% power to demonstrate that nasal congestion had no significant impact on the glucose AUEC 0-t under the same assumption.
3 | RESULTS
| Study participants
A total of 36 participants were enrolled in this study, 18 in each cohort. Baseline demographics were similar for both cohorts (Table S1) (Table 1) . T max was 18 minutes, both with nasal congestion and after recovery from cold symptoms. The glucagon PK observed during nasal congestion did not show any statistically significant differences compared to that after recovery from cold symptoms in this cohort (Table 2 ).
| Cohort 2
The glucagon profile for Cohort 2 was similar to the 2 profiles for Cohort 1 (Table 1) , with C max and AUC 0-t values for Cohort 2 falling between those for Cohort 1. T max was the same as that for both Cohort 1 profiles. There were no statistically significant differences between the profiles for Cohort 1 with nasal congestion and Cohort 1 without nasal congestion or the profile for Cohort 2 ( Table 2 ).
| Glucose pharmacodynamics 3.3.1 | Cohort 1
Blood glucose increased within 5 minutes after NG administration in participants with nasal congestion and after recovery from cold symptoms ( Figure 2B ) with similar profiles. Figure 2B ). Difference in LnAUEC 0-t values was not statistically significant between Cohort 1 with nasal congestion and Cohort 2 after adjusting for baseline glucose concentration (P = .503). No other statistically significant differences in PD parameters were observed ( Table 2) . 
| Cohort 2
Scores for Cohort 2 were between the 2 sets of scores for Cohort 1 and followed a similar pattern. The mean score rose within 15 minutes after NG administration and fell below baseline scores by 3 hours.
Among Cohort 2 participants, 78% had total symptom scores ≥2
prior to glucagon administration; this percentage was higher at 15 and 30 minutes after glucagon administration and returned to baseline 1 hour post dose ( Figure S2B ).
| Adverse events
No serious AEs were reported during this study (Table 3 b Median (minimum, maximum). Abbreviations: AUC 0-t , area under the curve from time zero; AUEC 0-t , area under the effect curve from time zero; C max , maximum concentration; CI, confidence interval; Ln, natural logarithm.
| Other safety measures
Blood pressure (BP) and pulse were measured 1 hour before NG administration and 45 minutes afterwards. Statistically-significant increases in BP were observed in each treatment group except for diastolic BP in Cohort 1 participants with cold symptoms, and were more pronounced with the use of nasal decongestant. There were no significant changes in pulse (Table S2) not result in a clinically-meaningful increase in glucose response. All NG treatments were generally well-tolerated. Many observed AEs were related to local tolerability, probably explained by the route of administration. Other AEs are well-known effects of glucagon administration. These events include nausea, vomiting and increased blood pressure. 6 Increased pulse rate is also observed generally with glucagon administration; however, we did not see a significant change in pulse rate in this study. Administration of oxymetazoline, which acts as a vasoconstrictor, 22 may also have contributed to the rise in blood pressure, which was more pronounced in participants treated with a decongestant.
Despite the presence of cold symptoms in this study, these PK, PD and safety results are similar to those observed in a study of glucagon in individuals with T1D who were not experiencing nasal congestion, 17 indicating that NG PK/PD were not significantly altered by nasal congestion, with or without use of a nasal decongestant. This is in contrast to a study of nasally-administered fentanyl, where absorption was somewhat compromised and T max was delayed by oxymetazoline administration.
11
Strengths of the study include having participants in Cohort 1 serve as their own controls, and the use of a single study centre, which ensured consistency. One potential limitation was the use of a single nasal decongestant, although we selected a decongestant that is among the most commonly used.
In summary, there were no clinically relevant differences in safety or PK/PD of NG associated with nasal congestion due to common cold or concomitant administration of nasal decongestant.
Although there were modest differences in total glucose excursions, the onset of glucose response and the glucose excursion observed in the first 30 minutes were similar across the 3 groups. Glucagon and glucose levels increased rapidly after treatment, peaking at 
